PDX Model

MSK-LX29

Share
Print
Share
Print

Sex: Female

Histology: Adenocarcinoma

Key Mutations: EGFR L858R, TP53 R248Q, MET Amplified,

ERBB2 Amplified

Molecular Characteristics: MSK-IMPACT

Matched Normal: Yes

Treatment: erlotinib

Site: Lung

Paired: No

Comments: erlotinib resistant

Licensing Information: Corporations and other for-profit entities may nonexclusively license Memorial Sloan Kettering’s tangible materials for research or commercial purposes. For more information, please contact TRMOTDRTM@mskcc.org.

Stage of Development

Ready to use